α-Hydroxytropolones: A new class of potent inhibitors of inositol monophosphatase and other bimetallic enzymes

Journal of the American Chemical Society

Volumn 119, Issue 14, 1997, Pages 3201-3204

  Piettre, Serge R ^a   Ganzhorn, Axel ^a   Hoflack, Jan ^a,b   Islam, Khalid ^a   Hornsperger, Jean Marie ^a  

^a SANOFI   (France)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ENZYME INHIBITOR; PHOSPHATASE; TROPOLONE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION;

EID: 0030909210     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja9634278     Document Type: Article

References (53)

1. Billington, D. C. The inositol Phosphates. Chemical Synthesis and Biological Significance; VCH Publisher: Wheinheim, 1991; pp 9-21.
2. (a) McAllister, G.; Whiting, P.; Hammond, E. A.; Knowles, M. R.; Atack, J. R.; Bailey, F. J.; Maigetter, R.; Ragan, C. I. Biochem. J. 1992, 284, 749-754.
3. (b) Bone, R.; Springer, J. P.; Atack, J. R. Proc. Natl. Acad. Sci. USA 1992, 89, 1031-1035.
4. (c) Bone, R.; Frank, L.; Springer, J. P.; Pollack, S. J.; Osborn S.; Atack, J. R. ; Knowles, M. R.; McAllister, G.; Ragan, C. I.; Broughton, H. B.; Baker, R.; Fletcher, S. R. Biochemistry 1994, 33, 9460-9467.
5. (d) Bone, R.; Frank, L.; Springer, J. P.; Atack, J. R. Biochemistry 1994, 33, 9468-9476.
6. (a) Greasley, P. J.; Gore M. G. FEBS Lett. 1993, 331, 114-118.
7. (b) Pollack, J. S.; Atack, J. R.; Knowles, M. R.; McAllister, G.; Ragan, C. I.; Baker, R.; Fletcher, S. R.; Iversen, L. L.; Broughton, H. B. Proc. Natl. Acad. Sci. USA 1994, 91, 5766-5770.
8. (c) Cole, A. G.; Gani, D. J. Chem. Soc., Perkin Trans. 1 1995, 2685-2694.
9. (d) Ganzhorn, A. J.; Lepage, P.; Pelton, P. D.; Strasser, F.; Vincendon, P., Rondeau, J.-M. Biochemistry 1996, 10957-10966.
10. (a) Berridge, M. J.; Downes, P. F.; Hanley, M. R. Biochem. J. 1982, 206, 587-595.
11. (b) Nahorski, S. R.; Ragan, C. I.; Challiss, R. A. J. Trends Pharmacol. Sci. 1991, 12, 297-303.
12. Peet, M.; Pratt, J. P. Drugs 1993, 46, 7-17.
13. (a) Atack, J. R.; Fletcher, S. R. Drugs of the Future 1994, 19, 857-866, and references cited therein (review article).
14. (b) van Steijn, A. M. P.; Willems, H. A. M.; de Boer, Th.; Geurts, J. L. T.; van Boeckel, C. A. A. Bioorg. Med. Chem. Lett. 1995, 5, 469-474.
15. (c) Schulz, J.; Wilkie, J.; Lightfoot, Ph.; Rutherford, T.; Gani, D. J. Chem. Soc., Chem. Commun. 1995, 2353-2356.
16. (d) Schnetz, N.; Guédat, Ph.; Spiess, B.; Schlewer, G. Bull. Soc. Chim. Fr. 1996, 133, 205-208.
17. Atack, J. R.; Cook, S. M.; Watt, A. P.; Fletcher, S. R.; Ragan, C. I. J. Neurochem. 1993, 60, 652-658.
18. Nozoe, T. Fortschr. Chem. Org. Naturst. 1956, 13, 232-301.
19. Islam, K.; Stefanelli, S.; Sponga, F.; Denaro, M. World Pat. 1996, WO9637197.
20. Including aliphatic, vinylic, and arylic derivatives; see also 6b.
21. Ganzhorn, A. J.; Rondeau, J.-M. Miami Nature Biotechnology Short Reports (Proceedings of the 1997 Miami Nature Biotechnology Winter Symposium, Oxford Press, Oxford, UK) 1997, 8, 61.
22. Wilkie, J.; Cole, A. G.; Gani, D. J. Chem. Soc., Perkin Trans. 1 1995, 2709-2727.
23. (a) Rossi, M.; Link, J.; Lee, J. C. Arch. Biochem. Biophys. 1984, 231, 470-478.
24. (b) Gable, R. W.; Mackay, M. F.; Banwell, M. G.; Lambert, J. N. Acta Crystallogr. C 1990, 46, 1308-1313.
25. (c) Gulbis, J. M.; Mackay, M. F.; Banwell, M. G.; Lambert, J. N. Acta Crystallogr. C 1992, 48, 332-338.
26. Takeshita, H.; Mori, A.; Kusaba, T.; Watanabe, H. Bull. Chem. Soc. Jpn 1987, 60, 4325-4333.
27. (a) Strasser, F.; Pelton, P. D.; Ganzhorn, A. J. Biochem. J. 1995, 307, 585-593.
28. (b) Cleland, W. W. Methods Enzymol. 1979, 63, 103-138.
29. (a) Abichandani, C. T.; Jaktar, S. K. K. J. Indian Inst. Sci. 1938, A21, 417-441.
30. (b) Yui, N. Sci. Repts Tôhoku Univ. First Ser. 1956, 40, 114-120.
31. a = 9.3). No inhibition could be measured at 1 mM concentration; technical problems with the enzymatic assay and the instability of deprotonated pyrogallol, however, complicate those experiments; a clear answer could not be obtained.
32. Bryant, B. E.; Fernelius, W. C.; Douglas, B. E. J. Am. Chem. Soc. 1953, 75, 3784-3786.
33. Kim, E. E.; Wyckoff, W. W. J. Mol. Biol. 1991, 218, 449-464.
34. (a) Klinman, J. P.; Krueger, M.; Brenner, M.; Edmondson, D. E. J. Biol. Chem. 1984, 259, 3399-3402.
35. (b) Goldstein, M.; Lauber, E.; McKereghan, M. R. Biochem. Pharmacol. 1964, 13, 1103-1106.
36. 22,20b In addition, the competitive or uncompetitive nature of inhibition with respect to the substrate argues against depletion of free metal ions, which is expected to give rise to noncompetitive inhibition. Finally, the different selectivity profiles, at least with IMPase and APase, clearly show that inhibition occurs through binding at the enzyme active site.
37. Bosron, W. F.; Anderson, R. A.; Falk, M. C.; Kennedy, F. S.; Vallee, B. L. Biochemistry 1977, 16, 610-614.
38. (a) Starnes, M. C.; Cheng, Y.-c. J. Biol. Chem. 1989, 264, 7073-7077.
39. (b) Davies, J. F.; Hostomska, Z.; Hostomsky, Z.; Jordan, S. R.; Matthews, D. A. Science, Washington D.C. 1991, 252, 88-95.
40. (c) Derbyshire, V.; Freemont, P. S.; Sanderson, M. R.; Beese, L.; Friedman, J. M.; Joyce, C. M.; Steitz, T. A. Science, Washington D.C. 1988, 240, 199-201.
41. (d) Freemont, P. S.; Friedman, J. M.; Beese, L.; Sanderson, M. R.; Steitz, T. A. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 8924-8928.
42. (e) Goldberg, J.; Huang, H.; Kwon, Y.; Greengard, P.; Nairn, A. C.; Kuriyan, J. Nature 1995, 376, 745-753.
43. (f) Kissinger, C. R.; Parge, H. E.; Knighton, D. R.; Lewis, C. T.; Pelletier, L. A.; Tempczyk, A.; Kalish, V. J.; Tucker, K. D.; Showalter, R. E.; Moomaw, E. W.; Gastinel, L. N.; Habuka, N.; Chen, X.; Maldonado, F.; Barker, J. E.; Bacquet, R.; Villafranca, J. E. Nature 1995, 378, 641-644.
44. de Boer, Th. J.; Backer, H. J. Organic Syntheses; Wiley: New York, 1963; Collect. Vol. IV, pp 250-253.
45. Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923-2924.
46. Cook, J. W.; Gibb, A. R.; Raphaël, R. A.; Somerville, A. R. J. Chem. Soc. 1951, 503-511.
47. All the analytical data obtained from our compound were in accordance with the structure of 3,5,7-tribromotropolone (1j); furthermore, it was successfully transformed into 3,5,7-trihydroxytropolone (1e). Hence we do not explain the discrepancy in the melting points.
48. 29
49. (a) Davis, A. L.; Keeler, J.; Lane, E.; Moskau, D. J. Magn. Reson. 1992, 98, 207-216.
50. (b) Bax, A.; Summers, M. F. J. Am. Chem. Soc. 1986, 108, 2093-2094.
51. Ragan, C. I.; Watling, K. J.; Gee, N. S.; Aspley, S.; Jackson, R. G.; Reid, G. G.; Baker, R.; Billington, B. C.; Barnaby, R. J.; Leeson, P. D. Biochem. J. 1988, 249, 143-148.
52. Bargar, T. M.; Broersma, R. J.; Creemer, L. C.; McCarthy, J. R.; Hornsperger, J. M.; Palfreyman, M. G.; Wagner, J.; Jung, M. J. J. Med. Chem. 1986, 29, 315-317.
53. Tripos Ass., 6548 Clayton Road, St Louis, MO 62177.